ACM
VRDN icon

Aster Capital Management’s Viridian Therapeutics VRDN Stock Holding History

Aster Capital Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,632
Closed -$35.2K – 1446
2025
Q3 		$35.2K Buy
+1,632
New +$29.4K 0.02% 567
2025
Q2 		– Sell
-393
Closed -$6.1K – 1614
2025
Q1 		$6.1K Buy
393
+24
+7% +$409 ﹤0.01% 1103
2024
Q4 		$7.07K Sell
369
-4,387
-92% -$95.4K ﹤0.01% 819
2024
Q3 		$108K Buy
+4,756
New +$77.8K 0.02% 366

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Aster Capital Management's VRDN Position: Q4 2025 in Review

Aster Capital Management sold out of Viridian Therapeutics (VRDN) in Q4 2025, closing a stake of 1,632 shares — an estimated $35.2K sold.

Aster Capital Management first reported a position in VRDN in Q3 2024 and held it in 4 quarters. The position peaked at $108K in Q3 2024. 229 funds tracked by Wall St. Rank hold VRDN as of Q4 2025.

  • Aster Capital Management reported no remaining Viridian Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Aster Capital Management sold 1,632 Viridian Therapeutics shares in Q4 2025, an estimated $35.2K.
  • Aster Capital Management first reported a position in Viridian Therapeutics in Q3 2024 and held it in 4 quarters.
  • Aster Capital Management's Viridian Therapeutics position peaked at $108K in Q3 2024.
  • 229 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q4 2025.

Based on Aster Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.